| Literature DB >> 25209713 |
Patrick Veiga1, Nicolas Pons2, Anurag Agrawal3, Raish Oozeer1, Denis Guyonnet1, Rémi Brazeilles4, Jean-Michel Faurie1, Johan E T van Hylckama Vlieg1, Lesley A Houghton5, Peter J Whorwell6, S Dusko Ehrlich7, Sean P Kennedy2.
Abstract
The gut microbiota (GM) consists of resident commensals and transient microbes conveyed by the diet but little is known about the role of the latter on GM homeostasis. Here we show, by a conjunction of quantitative metagenomics, in silico genome reconstruction and metabolic modeling, that consumption of a fermented milk product containing dairy starters and Bifidobacterium animalis potentiates colonic short chain fatty acids production and decreases abundance of a pathobiont Bilophila wadsworthia compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28). The GM changes parallel improvement of IBS state, suggesting a role of the fermented milk bacteria in gut homeostasis. Our data challenge the view that microbes ingested with food have little impact on the human GM functioning and rather provide support for beneficial health effects.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25209713 PMCID: PMC4160712 DOI: 10.1038/srep06328
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study design and overview of the bioinformatic pipeline used in this study.
Figure 2The FMP and MP modulate species of the gut microbiota.
(A,B) Relative abundance of the FMP-species measured in FMP (A) and MP (B) groups at baseline and after intervention. (C,D) Relative abundance of known or unknown (MGS) species measured in FMP (C) or MP (D) groups at baseline and after intervention. Only MGS that were significantly modulated are depicted. Statistical significance is reported by asteriks (*;p<0.05, ***;p<0.001; Wilcoxon-paired test corrected for multiple tests comparison using the Benjamini-Hochberg procedure). Results are presented using Tukey box-and-whisker plots as quartiles (25%, median, and 75%). Outliers were illustrated as single dots as per Tukey option of the Prism Graph software.
Taxonomic assignment of unknown species (MGS)
| MGS | Phylum | Order | Family | Genus |
|---|---|---|---|---|
| 109 | ||||
| 106 | ||||
| 146 | ||||
| 134 | ||||
| 126 | ||||
| 204 | ||||
| 203 |
The assignments were based on the MEGAN package57.
Figure 3Metabolic reconstruction of unknown gut microbial species shows a FMP-mediated increase of potential butyrate producers.
A) Projection on KEGG metabolic pathways of functions encoded by the MGS126 reconstructed genome (in red) using Ipath tool55. Functions of the KEGG global map were depicted underneath. B) Presence of genes predicted to encode enzymes of the butyrate synthesis pathway (thiolase EC 2.3.1.9 (THL); β-hydroxybutyryl-CoA dehydrogenase (BHCD; EC 1.1.1.35); crotonase (CRO; EC 4.2.1.17); butyryl-CoA dehydrogenase (BCD; EC 1.3.99.2); Electron-Transfer Flavoprotein α and β sub-units (ETFα and ETF β; E.C. 1.5.5.1); butyrate kinase (BK; EC 2.7.2.7); butyryl-coA acetyl-coA transferase (ButCoA; EC 2.8.3.8) among the reconstituted Clostridiales MGS. C) Abundance of butyrogenic modules of the human gut microbiota in the IBS cohort at baseline. Mean and standard deviation are represented. Results are presented using Tukey box-and-whisker plots.
Selected shared functions of FMP-modulated species
| Pathways/Functions | FMP-stimulated species | FMP-inhibited species | ||||
|---|---|---|---|---|---|---|
| MGS126 | MGS203 | |||||
| 6 | 6 | |||||
| 9 | 8 | 5 | 2 | 1 | 1 | |
| 1 | 2 | 2 | 3 | 2 | 2 | |
| 21 | 21 | |||||
| 18 | 18 | |||||
| 7 | 7 | |||||
| 3 | 3 | 3 | ||||
| 7 | 7 | |||||
| 1 | 1 | |||||
| 3 | 3 | |||||
| 7 | 7 | 1 | ||||
*Number of COG/per genome associated to pathway/functions.
Figure 4The FMP stimulates the production of butyrate by human colonic microbiota in vitro.
The SHIME colonic fermenter mimicking conditions of the acending, transverse and descending colons (reference 30) was inoculated with fecal microbiota of 2 healthy human donors (black and grey columns) and after 2 week (C1 & C2 time points) exposed to FMP during 3 weeks (T1, T2 and T3 time points). Mean fold changes between control and treatment periods are reported when statistical significance was met. n.s: non-significant, *** (p<0.001, ANOVA).